Aging is driven by the accumulation of senescent cells (SnCs), which evade immune clearance and fuel chronic inflammation, fibrosis, and tissue degeneration. GD3 (disialoganglioside) binds inhibitory receptors, such as Siglec-7, on natural killer (NK) cells, thereby suppressing their cytotoxic function against SnCs. This immune evasion mechanism accelerates aging-related diseases, including pulmonary fibrosis, liver cirrhosis, and osteoporosis.
Fig. 1 GD3 targeting in vivo reduces aging-related diseases. (Iltis C, et al., 2025)
CD BioSciences aims to help clients develop anti-aging drugs targeting GD3, which can restore immune surveillance, clear pathogenic senescent cells, and mitigate age-related dysfunction.
Types of Anti-Aging Drugs Targeting GD3 We Can Develop
Monoclonal antibody drugs targeting GD3
CD BioSciences supports clients in designing monoclonal antibodies (mAbs) that bind specifically to GD3. Our customized services include antibody design, screening, optimization, and characterization. We also offer research services to help clients understand how mAbs targeting GD3 modulate immune responses and reduce age-related inflammation.
Small molecule drugs targeting GD3
CD BioSciences uses high-throughput screening to identify small molecule drug candidates that can interact with GD3 and modulate its effects on aging. We offer end-to-end services for drug candidates targeting GD3, including design, synthesis, and optimization, combined with in vitro assays to evaluate their effects on cell proliferation and apoptosis.
Anti-Aging Drug Efficacy Evaluation Services
CD BioSciences employs a multifaceted approach to analyze the anti-aging effects of drug candidates targeting GD3 using in vitro and in vivo models, offering a comprehensive evaluation of drug efficacy.
Analysis of the Effects of Anti-Aging Drugs Targeting GD3 on Cellular Senescence
CD BioSciences offers a variety of assays using qPCR and flow cytometry techniques to assess the effects of anti-aging drugs targeting GD3 on cellular aging. Our experts help clients quantify key biomarkers of cellular senescence, including telomere length, senescence-associated beta-galactosidase activity, and expression levels of aging-related genes.
Analysis of the Effects of Anti-Aging Drugs Targeting GD3 on Targeted Apoptosis of Senescent Cells
Apoptosis is a highly regulated process that can influence GD3 expression levels. CD BioSciences employs comprehensive methodologies, including detecting apoptosis markers (e.g., caspases, Bcl-2 family proteins) by Western blotting, to evaluate how drugs impact targeted apoptosis in senescent cells. Additionally, we offer high-content imaging services to visualize cellular responses in real time, capturing the dynamic interplay between GD3 and apoptotic pathways.
We also evaluate the efficacy of anti-aging drugs targeting GD3 in appropriate in vivo models. We help clients perform histological analysis of tissues (e.g., liver, skin) to evaluate the effects of drug candidates on senescent cells.
Targeting GD3 in anti-aging drug discovery holds significant promise for mitigating the effects of aging and promoting lifespan. CD BioSciences offers customized services encompassing preclinical drug development and biomarker discovery for anti-aging drugs targeting GD3. If you are interested in our services, please feel free to contact us or make an online inquiry.
References
- Iltis C, et al. A ganglioside-based immune checkpoint enables senescent cells to evade immunosurveillance during aging. Nat Aging, 2025, 5 (2): 219-236.
- Malisan F, Testi R. GD3 in cellular ageing and apoptosis. Exp Gerontol, 2002, 37 (10-11): 1273-82.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
